Chinese Manufacturing Giant CATL Launches Record-Breaking IPO for New Battery Plant
The largest global IPO of the year aims to fund a significant expansion of battery production in Hungary.
Contemporary Amperex Technology Co. Limited (CATL), a leading Chinese battery manufacturer, has announced an initial public offering (IPO) to offer approximately 117.9 million shares at an unit price of €30.37, marking what is poised to be the largest IPO of the year globally and Hong Kong's largest since Midea raised €4.1 billion in a similar manner.
Interest in the IPO has surged, with nearly 20 prominent investors pledging support, including Sinopec and the Kuwaiti sovereign fund, which have already committed to purchasing shares worth approximately €2.36 billion.
Out of the total funds raised, about 90%, or €3.2 billion, is earmarked for the development of a new battery manufacturing facility in Hungary.
This facility aims to produce batteries for major automotive manufacturers in Europe, including BMW, Stellantis, and Volkswagen.
The first phase of construction, estimated at €2.7 billion, is projected for completion within this year, at which point production of batteries is expected to commence.
Subsequent phases will be entirely funded through proceeds from the IPO, allowing CATL to solidify its presence in the European market.
In a related development, a Beijing-based company is engaged in negotiations with Swiss postal branch Post Auto to introduce robotaxi services in Switzerland, with testing anticipated by the end of the year.
The company is also eyeing the Turkish market for expansion.
In China, Apollo Go operates one of the largest fleets of robotaxis across cities including Beijing and Wuhan.
In Wuhan, the operational challenges of autonomous vehicles have raised concerns among residents and taxi drivers about job displacement.
Moreover, Uber has announced a strategic partnership with three Chinese startups specializing in autonomous driving: Pony.ai, Momenta, and WeRide.
The partnership aims to integrate their technology into Uber's platform for international markets, including Europe.
The first implementation of Momenta’s technology in Uber's robotaxis is expected in early 2026, with safety operators present in the vehicles during the initial phase.
The collaboration with Momenta was disclosed on May 2.
Meanwhile, Hyundai Motor Group is reportedly contemplating a return to the Russian market after officially exiting in December 2023. Following the sale of its St. Petersburg plant for approximately $100, Hyundai has indicated the possibility of repurchasing within two years, as stipulated in their agreement.
Recently, Hyundai and Kia have registered over 20 trademarks for vehicles and parts in Russia, approved by the Russian Federal Service for Intellectual Property.
Notably, Hyundai's interest in re-entering the Russian market coincides with ongoing peace negotiations between Russia and Ukraine, as well as Russia increasing tariffs on imported vehicles since October, affecting Chinese brands.
In the first half of 2024, Chinese cars constituted over 80% of total car imports into Russia, but this figure halved in the first two months of 2025. Reports suggest that the Kremlin expects higher tariffs to encourage Chinese companies to establish local production; however, interest among such firms remains low, presenting an opening for Hyundai.
Additionally, Swiss pharmaceutical giant Roche plans to build a new biopharmaceutical factory in the high-tech park of Zhangjiang, spanning approximately 35,300 square meters.
This facility will focus on producing Vabysmo, a bispecific antibody approved for treating eye diseases, in response to the surging demand for innovative drugs in China.
Construction is anticipated to be completed by 2029, with operations starting in 2031. Roche states that this investment will fortify its pharmaceutical supply chain in China, enhance local production capabilities, and reflect its commitment to the Chinese market.
In March, AstraZeneca signed a historic $2.5 billion investment agreement in Beijing, establishing a global strategic research and development center, underlining the significance of China's healthcare market in the global pharmaceutical supply chain.
Similarly, Eli Lilly launched its first joint laboratory platform outside the US, in Beijing, highlighting the rapid pace of innovation in China's biopharmaceutical sector.
Interest in the IPO has surged, with nearly 20 prominent investors pledging support, including Sinopec and the Kuwaiti sovereign fund, which have already committed to purchasing shares worth approximately €2.36 billion.
Out of the total funds raised, about 90%, or €3.2 billion, is earmarked for the development of a new battery manufacturing facility in Hungary.
This facility aims to produce batteries for major automotive manufacturers in Europe, including BMW, Stellantis, and Volkswagen.
The first phase of construction, estimated at €2.7 billion, is projected for completion within this year, at which point production of batteries is expected to commence.
Subsequent phases will be entirely funded through proceeds from the IPO, allowing CATL to solidify its presence in the European market.
In a related development, a Beijing-based company is engaged in negotiations with Swiss postal branch Post Auto to introduce robotaxi services in Switzerland, with testing anticipated by the end of the year.
The company is also eyeing the Turkish market for expansion.
In China, Apollo Go operates one of the largest fleets of robotaxis across cities including Beijing and Wuhan.
In Wuhan, the operational challenges of autonomous vehicles have raised concerns among residents and taxi drivers about job displacement.
Moreover, Uber has announced a strategic partnership with three Chinese startups specializing in autonomous driving: Pony.ai, Momenta, and WeRide.
The partnership aims to integrate their technology into Uber's platform for international markets, including Europe.
The first implementation of Momenta’s technology in Uber's robotaxis is expected in early 2026, with safety operators present in the vehicles during the initial phase.
The collaboration with Momenta was disclosed on May 2.
Meanwhile, Hyundai Motor Group is reportedly contemplating a return to the Russian market after officially exiting in December 2023. Following the sale of its St. Petersburg plant for approximately $100, Hyundai has indicated the possibility of repurchasing within two years, as stipulated in their agreement.
Recently, Hyundai and Kia have registered over 20 trademarks for vehicles and parts in Russia, approved by the Russian Federal Service for Intellectual Property.
Notably, Hyundai's interest in re-entering the Russian market coincides with ongoing peace negotiations between Russia and Ukraine, as well as Russia increasing tariffs on imported vehicles since October, affecting Chinese brands.
In the first half of 2024, Chinese cars constituted over 80% of total car imports into Russia, but this figure halved in the first two months of 2025. Reports suggest that the Kremlin expects higher tariffs to encourage Chinese companies to establish local production; however, interest among such firms remains low, presenting an opening for Hyundai.
Additionally, Swiss pharmaceutical giant Roche plans to build a new biopharmaceutical factory in the high-tech park of Zhangjiang, spanning approximately 35,300 square meters.
This facility will focus on producing Vabysmo, a bispecific antibody approved for treating eye diseases, in response to the surging demand for innovative drugs in China.
Construction is anticipated to be completed by 2029, with operations starting in 2031. Roche states that this investment will fortify its pharmaceutical supply chain in China, enhance local production capabilities, and reflect its commitment to the Chinese market.
In March, AstraZeneca signed a historic $2.5 billion investment agreement in Beijing, establishing a global strategic research and development center, underlining the significance of China's healthcare market in the global pharmaceutical supply chain.
Similarly, Eli Lilly launched its first joint laboratory platform outside the US, in Beijing, highlighting the rapid pace of innovation in China's biopharmaceutical sector.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
